Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.

The Echelon-3 study seemed doomed, but it just read out positively for overall survival.

New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.

Of the big oncology deals since 2016, there are still plenty that could go either way.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.